Thymosin Alpha-1 and Muscle Preservation: What the Evidence Shows

Does Thymosin Alpha-1 Preserve Muscle?

The direct answer is no one knows, because the necessary human trials have not been done. A convincing muscle-preservation study would prospectively measure outcomes such as appendicular lean mass, total lean mass, grip strength, chair-rise performance, gait speed, or another validated physical-function endpoint. The published TA1 literature cited here does not provide such a trial.

TA1 has immune-modulating effects and has been studied in infectious disease, sepsis, cancer adjunct settings, and other conditions. That creates a research hypothesis because inflammation can contribute to muscle catabolism. It does not establish that changing an immune marker with TA1 preserves skeletal muscle in a person losing weight, aging, recovering from illness, receiving testosterone, or using a GLP-1-based medicine.

The distinction matters: lean body mass is not identical to skeletal muscle, and a change in cytokines is not a substitute for a measured change in muscle mass, strength, or function.

What the TA1 Clinical Trials Actually Studied

ETASS: an older severe-sepsis trial, not a muscle trial

The 2013 ETASS study randomized 361 patients with severe sepsis to TA1 plus standard care or standard care alone. Reported 28-day mortality was 26.0% with TA1 and 35.0% in the control group. However, the prespecified chi-square comparison was not statistically significant (P=0.062); a log-rank analysis was P=0.049, and the reported relative risk was 0.74 with a 95% confidence interval of 0.54 to 1.02. The confidence interval included no effect (ETASS, PMID 23327199).

Those results were worth further study, but they did not demonstrate muscle preservation. The trial measured mortality and immune-function outcomes in severe sepsis, not lean mass, strength, rehabilitation, or sarcopenia.

TESTS: the larger phase 3 trial found no mortality benefit

The 2025 TESTS trial was multicenter, double-blind, randomized, and placebo controlled. Of 1,106 enrolled adults with sepsis, 1,089 were included in the modified intention-to-treat analysis. Twenty-eight-day mortality was 23.4% with TA1 and 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27; P=0.93). The investigators concluded that there was no clear evidence TA1 reduced 28-day mortality (TESTS, PMID 39814420).

TESTS does not answer the muscle question either, but it is important context. It prevents the older, less definitive ETASS result from being presented as proof that TA1 meaningfully reverses catabolic illness.

Reviews describe immune biology, not proven muscle benefit

A comprehensive TA1 review summarizes proposed immune mechanisms and studies across several diseases. It does not establish a clinical indication, dose, or outcome for muscle preservation (PMID 33362999). Statements that TA1 directly suppresses muscle-specific ubiquitin ligases, stimulates satellite cells, restores mitochondrial biogenesis, or prevents sarcopenia should not be treated as human clinical findings without direct supporting trials.

GLP-1 Weight Loss and Lean Mass: The Relevant Evidence

People searching for TA1 muscle preservation often want to protect muscle during semaglutide or tirzepatide treatment. Body-composition changes deserve attention, but the evidence does not support adding TA1.

Semaglutide: STEP 1 exploratory DXA analysis

In an exploratory DXA analysis of 140 STEP 1 participants, semaglutide reduced body weight by 15.0%, total fat mass by 19.3%, and total lean body mass by 9.7% from baseline. Because fat mass declined more, the proportion of body weight represented by lean mass increased by about three percentage points (STEP 1 body-composition analysis).

This result should not be translated into “muscle loss” without qualification. DXA lean mass includes water, organs, connective tissue, and other fat-free tissue, not only skeletal muscle. The analysis was exploratory, involved a subset of the trial, and did not test TA1.

Tirzepatide: SURMOUNT-1 DXA substudy

In the SURMOUNT-1 DXA substudy, tirzepatide reduced body weight by 21.3%, fat mass by 33.9%, and lean mass by 10.9% at 72 weeks. About 75% of weight lost was fat mass and 25% was lean mass (PMID 39996356). The proportions were broadly consistent across the post hoc subgroups studied.

Again, this was not a TA1 study. It supports monitoring nutrition, function, and body composition when clinically appropriate; it does not identify an immune peptide as a solution.

What Is Known About Preserving Muscle During Weight Loss

For a patient concerned about weakness or loss of function, the first task is to distinguish expected weight-loss composition from clinically important muscle loss. Useful questions include:

• Has strength or physical performance declined?
• Is weight loss faster than intended, or is food intake inadequate?
• Is there a new illness, prolonged inactivity, endocrine disorder, neurologic problem, or medication effect?
• Is protein and total energy intake adequate for the person's age, kidney function, activity, and treatment plan?
• Is the person doing progressive resistance exercise suited to their ability and medical status?

Resistance training and adequate nutrition have a far stronger evidence base for supporting muscle health than TA1. Older adults, people with frailty, and patients with major illness may need individualized assessment by a clinician, dietitian, or physical therapist. A scale or DXA result alone does not diagnose sarcopenia.

No published controlled trial shows that pairing TA1 with semaglutide, tirzepatide, testosterone therapy, amino-acid supplements, or another peptide improves lean mass or function. Lists of “stacks,” cycles, loading phases, or laboratory panels are therefore not evidence-based TA1 muscle-preservation protocols.

Is There a Thymosin Alpha-1 Muscle-Preservation Dose?

No. Doses used in hepatitis, sepsis, or oncology research were selected for those diseases and outcomes. They cannot be repurposed as validated dosing guidance for weight loss, aging, frailty, or bodybuilding.

There is also no validated treatment duration, cycling schedule, response timeline, baseline laboratory panel, or monitoring interval for TA1 muscle preservation. Without evidence of benefit, a protocol cannot be made reliable by adding more tests or more detailed instructions.

FDA Status and Compounding Concerns

There is no FDA-approved TA1 product in the United States. A compounded medicine is not FDA-approved, and FDA does not review compounded products for safety, effectiveness, or quality before marketing.

FDA lists TA1 among bulk substances that may present significant safety risks in compounding. The agency specifically cites potential immunogenicity for certain routes, peptide-related impurities, active-ingredient-characterization complexity, and inadequate safety information (FDA compounding risk list).

At its December 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against placing both TA1 free base and TA1 acetate on the section 503A Bulks List, citing a lack of convincing effectiveness data (FDA meeting summary). That committee vote is regulatory evidence about compounding, not a clinical trial, but it is directly relevant to claims that a compounded TA1 product is an established therapeutic option.

When Muscle Loss Needs Medical Evaluation

Prompt evaluation is appropriate when weight loss is unplanned, weakness is progressive, falls occur, daily activities become harder, swallowing is impaired, or muscle loss accompanies fever, pain, bleeding, neurologic symptoms, or other signs of illness. Those findings call for a cause-focused assessment, not an experimental peptide protocol.

For people using a weight-management medicine, a useful follow-up focuses on weight trajectory, dietary intake, adverse effects that limit eating or hydration, strength and function, and the underlying reason for treatment. Medication changes should be made with the prescriber rather than in response to an online lean-mass percentage.